Centene (NYSE:CNC) Given New $58.00 Price Target at Truist Financial

Key Points

• Truist raised its price target on Centene to $58 (from $49) and kept a "buy" rating, implying about a 10.3% upside from the prior close.
• Centene reported a strong Q1, beating EPS ($3.37 vs. $2.12) and revenue estimates and raising 2026 EPS guidance after improved medical-cost controls, which drove the stock higher.
• Despite recent upgrades, the analyst landscape is mixed with a MarketBeat consensus of "Hold" (average target ~$49.76), and risks include a ~2 million drop in ACA enrollment and continued commercial membership softness.

Centene (NYSE:CNC - Get Free Report) had its price target lifted by stock analysts at Truist Financial from $49.00 to $58.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's price target suggests a potential upside of 10.26% from the company's previous close.

CNC has been the subject of several other reports. Wells Fargo & Company set a $44.00 price objective on shares of Centene and gave the stock an "equal weight" rating in a research note on Wednesday, February 18th. Sanford C. Bernstein reiterated an "outperform" rating and issued a $59.00 price target on shares of Centene in a report on Tuesday, January 6th. Barclays reissued an "overweight" rating and set a $63.00 price target on shares of Centene in a research note on Wednesday. JPMorgan Chase & Co. cut their price objective on Centene from $45.00 to $41.00 and set a "neutral" rating on the stock in a research report on Thursday, March 19th. Finally, Mizuho set a $41.00 target price on Centene and gave the stock a "neutral" rating in a research report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $49.76.

Centene Stock Performance

Shares of NYSE:CNC traded up $3.03 during mid-day trading on Wednesday, reaching $52.60. 2,817,833 shares of the company traded hands, compared to its average volume of 6,445,257. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.10 and a quick ratio of 1.10. Centene has a 52 week low of $25.08 and a 52 week high of $64.15. The firm has a market cap of $25.87 billion, a PE ratio of -3.89, a PEG ratio of 0.96 and a beta of 0.59. The company's 50 day moving average price is $38.49 and its 200-day moving average price is $39.24.

Centene (NYSE:CNC - Get Free Report) last released its earnings results on Tuesday, April 28th. The company reported $3.37 earnings per share for the quarter, beating analysts' consensus estimates of $2.12 by $1.25. The company had revenue of $49.94 billion for the quarter, compared to analysts' expectations of $47.58 billion. Centene had a negative net margin of 3.43% and a positive return on equity of 4.25%. Centene's revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.90 EPS. On average, equities analysts expect that Centene will post 3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Centene

Several hedge funds have recently modified their holdings of CNC. Vanguard Group Inc. boosted its position in Centene by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 56,978,753 shares of the company's stock valued at $2,344,676,000 after acquiring an additional 190,334 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Centene by 117.0% during the 4th quarter. AQR Capital Management LLC now owns 31,798,738 shares of the company's stock worth $1,308,518,000 after acquiring an additional 17,143,904 shares in the last quarter. Geode Capital Management LLC lifted its position in Centene by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 13,271,492 shares of the company's stock valued at $554,338,000 after acquiring an additional 697,277 shares during the last quarter. Deerfield Management Company L.P. lifted its position in Centene by 184.0% during the third quarter. Deerfield Management Company L.P. now owns 9,046,000 shares of the company's stock valued at $322,761,000 after acquiring an additional 5,860,630 shares during the last quarter. Finally, Morgan Stanley grew its holdings in Centene by 7.2% in the fourth quarter. Morgan Stanley now owns 9,002,570 shares of the company's stock worth $370,456,000 after purchasing an additional 603,585 shares during the last quarter. Hedge funds and other institutional investors own 93.63% of the company's stock.

More Centene News

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — Centene reported adjusted EPS well above estimates ($3.37 vs. consensus ~ $2.12), revenue beat, and raised 2026 EPS guidance after improving medical-cost controls. This is the primary driver of the stock move. PR Newswire
• Positive Sentiment: Cost controls + Medicaid strength — Management cited declining medical costs and stronger Medicaid performance, improving margins and lifting investor confidence in near-term profitability. Reuters
• Positive Sentiment: Bank of America upgraded CNC to Buy with a $60 price target (from $34), backing the rebound story and providing further buy-side support. Benzinga
• Positive Sentiment: Unusual bullish options flow — Large purchases of call options (≈19,116 contracts) indicate short-term speculative/hedge positioning ahead of/after the print (possible short-covering or directional bets).
• Neutral Sentiment: Earnings-call tone mixed — The Q1 call showed strong results but a cautious management tone on outlook details and membership trends; watch commentary for FY cadence. TipRanks
• Neutral Sentiment: Mixed analyst landscape — Some upgrades and higher targets (e.g., BofA) but a wide range of price targets and recent sell/hold calls leave consensus still mixed; volatility in estimates likely. QuiverQuant
• Negative Sentiment: ACA (Obamacare) enrollment drop — Reports show a ~2 million decline in individual-market enrollment after subsidy changes, a structural headwind for Centene’s individual business going forward. Forbes
• Negative Sentiment: Commercial enrollment slide persists — While Medicaid helped, commercial membership softness remains a risk to revenue growth and could temper margin gains. Benzinga
• Negative Sentiment: Insider selling and large institutional rebalancing — Recent insider stock sales and big fund position turnover could keep selling pressure at times. QuiverQuant

About Centene

Centene Corporation NYSE: CNC is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children's Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene's offerings extend beyond traditional insurance to include a range of specialty and support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.